-
Axsome Therapeutics Inc. NASDAQ:AXSM Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.
Location: 22 Cortlandt Street, 16Th Floor, New York, 10007, US | Website: www.axsome.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.438B
Cash
327.3M
Avg Qtr Burn
-33.14M
Short % of Float
19.59%
Insider Ownership
16.68%
Institutional Own.
81.12%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AUVELITY [AXS-05] (NMDA receptor antagonist & sigma-1 agonist) Details Major depressive disorder, Mental health | Approved Quarterly sales | |
Sunosi® (solriamfetol) Details Mental health, Excessive daytime sleepiness | Approved Quarterly sales | |
PDUFA Approval decision | ||
AXS-14 (esreboxetine) (NE reuptake inhibitor) Details Pain, Muscle pain, Fibromyalgia | NDA Submission | |
Solriamfetol Details Shift work disorder | Phase 3 Data readout | |
Solriamfetol Details Binge eating disorder | Phase 3 Data readout | |
Solriamfetol Details Attention deficit hyperactivity disorder | Phase 3 Data readout | |
Solriamfetol Details Major depressive disorder | Phase 3 Data readout | |
AXS-05 (NMDA receptor antagonist & sigma-1 agonist) Details Alzheimer's disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
AXS-05 (NMDA receptor antagonist & sigma-1 agonist) Details Alzheimer's disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Phase 3 Update | ||
AXS-05 (NMDA receptor antagonist & sigma-1 agonist) Details Smoking cessation | Phase 2/3 Initiation |